Aura Biosciences, Inc.
AURA
$0.28
Change (1 day)
$12.38
Year High
$6.63
Year Low
Categories
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Aura Biosciences, Inc. (AURA) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -21,506,000 | 29.23 M | 255.08 M | 231.79 M | |
| 2022 | -100,724,000 | 28.35 M | 223.94 M | 196.7 M | |
| 2021 | -148,088,000 | 7.72 M | 160.03 M | 153.7 M | |
| 2020 | -17,378,000 | 130.82 M | 22.1 M | 18.46 M | |
| 2019 | -32,400,000 | 124.46 M | 37.06 M | 33.35 M |